Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Apitope Announces Completion of Enrolment in Phase IIA Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
Laminin-411 Is a Vascular Ligand for MCAM and Facilitates TH17 Cell Entry into the CNS.
Neuromyelitis optica.
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)
[Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain. Reply].
The Submaximal Clinical Exercise Tolerance Test (SXTT) to Establish Safe Exercise Prescription Parameters for Patients with Chronic Disease and Disability.
Lodonal/LDN
The ketogenic diet as a treatment paradigm for diverse neurological disorders.
Potential T cell epitopes of Mycobacterium tuberculosis that can instigate molecular mimicry against host: implications in autoimmune pathogenesis.
Mapi Pharma granted United States patent covering glatiramer depot for multiple sclerosis
Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis.
The influence of ethnicity on the characteristics of multiple sclerosis: A local population study between Persians and Arabs.
The AusD Study: A Population-based Study of the Determinants of Serum 25-Hydroxyvitamin D Concentration Across a Broad Latitude Range.
Brain gadolinium enhancement along the ventricular and leptomeningeal regions in patients with aquaporin-4 antibodies in cerebral spinal fluid.
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.
Magnetic resonance imaging in multiple sclerosis - patients' experiences, information interests and responses to an education programme.
Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).
Long-term effects of dalfampridine in patients with multiple sclerosis.
Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.
Sanofi sees US FDA ruling for MS drug Lemtrada in Q4
Memory rehabilitation for people with multiple sclerosis.
Treatment selection and experience in multiple sclerosis: survey of neurologists.
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
Diagnosis of exclusion: a case report of probable glatiramer acetate-induced eosinophilic myocarditis.
Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ).

Pages